XML 70 R54.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2018 | Oct. 01, 2017 | Sep. 30, 2018 | Oct. 01, 2017
Sales by segment of business |  |  |  |
Sales to customers | $ 20,348 | $ 19,650 | $ 61,187 | $ 56,255
Percent Change (as a percent) | 3.60% |  | 8.80% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,664 | 10,290 | $ 31,255 | 29,394
Percent Change (as a percent) | 3.60% |  | 6.30% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9,684 | 9,360 | $ 29,932 | 26,861
Percent Change (as a percent) | 3.50% |  | 11.40% |
CONSUMER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,415 | 3,356 | $ 10,317 | 10,062
Percent Change (as a percent) | 1.80% |  | 2.50% |
CONSUMER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,370 | 1,285 | $ 4,282 | 4,186
Percent Change (as a percent) | 6.60% |  | 2.30% |
CONSUMER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,045 | 2,071 | $ 6,035 | 5,876
Percent Change (as a percent) | (1.30%) |  | 2.70% |
CONSUMER | Baby Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 472 | 477 | $ 1,385 | 1,426
Percent Change (as a percent) | (1.00%) |  | (2.90%) |
CONSUMER | Baby Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 120 | 100 | $ 306 | 326
Percent Change (as a percent) | 20.00% |  | (6.10%) |
CONSUMER | Baby Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 352 | 377 | $ 1,079 | 1,100
Percent Change (as a percent) | (6.60%) |  | (1.90%) |
CONSUMER | Beauty |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,078 | 1,033 | $ 3,271 | 3,090
Percent Change (as a percent) | 4.40% |  | 5.90% |
CONSUMER | Beauty | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 543 | 523 | $ 1,791 | 1,739
Percent Change (as a percent) | 3.80% |  | 3.00% |
CONSUMER | Beauty | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 535 | 510 | $ 1,480 | 1,351
Percent Change (as a percent) | 4.90% |  | 9.50% |
CONSUMER | Oral Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 384 | 382 | $ 1,156 | 1,138
Percent Change (as a percent) | 0.50% |  | 1.60% |
CONSUMER | Oral Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 158 | 154 | $ 472 | 460
Percent Change (as a percent) | 2.60% |  | 2.60% |
CONSUMER | Oral Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 226 | 228 | $ 684 | 678
Percent Change (as a percent) | (0.90%) |  | 0.90% |
CONSUMER | OTC |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,048 | 1,002 | $ 3,186 | 3,021
Percent Change (as a percent) | 4.60% |  | 5.50% |
CONSUMER | OTC | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 440 | 401 | $ 1,359 | 1,310
Percent Change (as a percent) | 9.70% |  | 3.70% |
CONSUMER | OTC | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 608 | 601 | $ 1,827 | 1,711
Percent Change (as a percent) | 1.20% |  | 6.80% |
CONSUMER | Women's Health |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 269 | 270 | $ 792 | 788
Percent Change (as a percent) | (0.40%) |  | 0.50% |
CONSUMER | Women's Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 10 | 9
Percent Change (as a percent) | 0.00% |  | 11.10% |
CONSUMER | Women's Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 266 | 267 | $ 782 | 779
Percent Change (as a percent) | (0.40%) |  | 0.40% |
CONSUMER | Wound Care/Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 164 | 192 | $ 527 | 599
Percent Change (as a percent) | (14.60%) |  | (12.00%) |
CONSUMER | Wound Care/Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 106 | 104 | $ 344 | 342
Percent Change (as a percent) | 1.90% |  | 0.60% |
CONSUMER | Wound Care/Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 58 | 88 | $ 183 | 257
Percent Change (as a percent) | (34.10%) |  | (28.80%) |
PHARMACEUTICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,346 | 9,695 | $ 30,544 | 26,575
Percent Change (as a percent) | 6.70% |  | 14.90% |
PHARMACEUTICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,097 | 5,816 | $ 17,350 | 15,698
Percent Change (as a percent) | 4.80% |  | 10.50% |
PHARMACEUTICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,249 | 3,879 | $ 13,194 | 10,877
Percent Change (as a percent) | 9.50% |  | 21.30% |
PHARMACEUTICAL | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,398 | 3,269 | $ 9,778 | 9,158
Percent Change (as a percent) | 3.90% |  | 6.80% |
PHARMACEUTICAL | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,400 | 2,420 | $ 6,717 | 6,644
Percent Change (as a percent) | (0.80%) |  | 1.10% |
PHARMACEUTICAL | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 998 | 849 | $ 3,061 | 2,514
Percent Change (as a percent) | 17.60% |  | 21.80% |
PHARMACEUTICAL | Immunology | REMICADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,379 | 1,647 | $ 4,088 | 4,849
Percent Change (as a percent) | (16.30%) |  | (15.70%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 987 | 1,206 | $ 2,821 | 3,452
Percent Change (as a percent) | (18.20%) |  | (18.30%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 100 | 156 | $ 346 | 448
Percent Change (as a percent) | (35.90%) |  | (22.80%) |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 292 | 285 | $ 921 | 949
Percent Change (as a percent) | 2.50% |  | (3.00%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 536 | 476 | $ 1,602 | 1,343
Percent Change (as a percent) | 12.60% |  | 19.30% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 281 | 242 | $ 779 | 701
Percent Change (as a percent) | 16.10% |  | 11.10% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 255 | 234 | $ 823 | 642
Percent Change (as a percent) | 9.00% |  | 28.20% |
PHARMACEUTICAL | Immunology | STELARA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,310 | 1,124 | $ 3,712 | 2,930
Percent Change (as a percent) | 16.50% |  | 26.70% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 889 | 800 | $ 2,460 | 2,027
Percent Change (as a percent) | 11.10% |  | 21.40% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 421 | 324 | $ 1,252 | 903
Percent Change (as a percent) | 29.90% |  | 38.60% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 173 | 22 | $ 376 | 36
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 143 | 16 | 311 | 16
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 30 | 6 | 65 | 20
PHARMACEUTICAL | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 823 | 813 | $ 2,502 | 2,354
Percent Change (as a percent) | 1.20% |  | 6.30% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 345 | 353 | $ 1,006 | 1,020
Percent Change (as a percent) | (2.30%) |  | (1.40%) |
PHARMACEUTICAL | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 478 | 460 | $ 1,496 | 1,334
Percent Change (as a percent) | 3.90% |  | 12.10% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 202 | 194 | $ 623 | 522
Percent Change (as a percent) | 4.10% |  | 19.30% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 13 | 15 | $ 42 | 44
Percent Change (as a percent) | (13.30%) |  | (4.50%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 189 | 179 | $ 581 | 478
Percent Change (as a percent) | 5.60% |  | 21.50% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 490 | 467 | $ 1,460 | 1,351
Percent Change (as a percent) | 4.90% |  | 8.10% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 297 | 287 | $ 847 | 824
Percent Change (as a percent) | 3.50% |  | 2.80% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 193 | 180 | $ 613 | 527
Percent Change (as a percent) | 7.20% |  | 16.30% |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 131 | 152 | $ 419 | 481
Percent Change (as a percent) | (13.80%) |  | (12.90%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 35 | 51 | $ 117 | 152
Percent Change (as a percent) | (31.40%) |  | (23.00%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 96 | 101 | $ 302 | 329
Percent Change (as a percent) | (5.00%) |  | (8.20%) |
PHARMACEUTICAL | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,490 | 1,498 | $ 4,577 | 4,462
Percent Change (as a percent) | (0.50%) |  | 2.60% |
PHARMACEUTICAL | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 651 | 647 | $ 1,914 | 1,931
Percent Change (as a percent) | 0.60% |  | (0.90%) |
PHARMACEUTICAL | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 839 | 851 | $ 2,663 | 2,531
Percent Change (as a percent) | (1.40%) |  | 5.20% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 157 | 198 | $ 513 | 588
Percent Change (as a percent) | (20.70%) |  | (12.80%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 57 | 100 | $ 191 | 284
Percent Change (as a percent) | (43.00%) |  | (32.70%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 100 | 98 | $ 322 | 304
Percent Change (as a percent) | 2.00% |  | 5.90% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 749 | 643 | $ 2,165 | 1,876
Percent Change (as a percent) | 16.50% |  | 15.40% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 468 | 395 | $ 1,306 | 1,154
Percent Change (as a percent) | 18.50% |  | 13.20% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 281 | 248 | $ 859 | 722
Percent Change (as a percent) | 13.30% |  | 19.00% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 175 | 194 | $ 559 | 608
Percent Change (as a percent) | (9.80%) |  | (8.10%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 76 | 87 | $ 238 | 273
Percent Change (as a percent) | (12.60%) |  | (12.80%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 99 | 107 | $ 321 | 335
Percent Change (as a percent) | (7.50%) |  | (4.20%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 409 | 463 | $ 1,340 | 1,390
Percent Change (as a percent) | (11.70%) |  | (3.60%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 50 | 65 | $ 179 | 220
Percent Change (as a percent) | (23.10%) |  | (18.60%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 359 | 398 | $ 1,161 | 1,170
Percent Change (as a percent) | (9.80%) |  | (0.80%) |
PHARMACEUTICAL | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,588 | 1,898 | $ 7,355 | 5,219
Percent Change (as a percent) | 36.40% |  | 40.90% |
PHARMACEUTICAL | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,250 | 846 | $ 3,268 | 2,207
Percent Change (as a percent) | 47.80% |  | 48.10% |
PHARMACEUTICAL | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,338 | 1,052 | $ 4,087 | 3,012
Percent Change (as a percent) | 27.20% |  | 35.70% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 498 | 317 | $ 1,441 | 871
Percent Change (as a percent) | 57.10% |  | 65.40% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 318 | 230 | $ 880 | 643
Percent Change (as a percent) | 38.30% |  | 36.90% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 180 | 87 | $ 561 | 228
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 705 | 512 | $ 1,912 | 1,371
Percent Change (as a percent) | 37.70% |  | 39.50% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 334 | 230 | $ 811 | 622
Percent Change (as a percent) | 45.20% |  | 30.40% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 371 | 282 | $ 1,101 | 749
Percent Change (as a percent) | 31.60% |  | 47.00% |
PHARMACEUTICAL | Oncology | VELCADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 271 | 273 | $ 864 | 843
Percent Change (as a percent) | (0.70%) |  | 2.50% |
PHARMACEUTICAL | Oncology | VELCADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Oncology | VELCADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 271 | 273 | $ 864 | 843
Percent Change (as a percent) | (0.70%) |  | 2.50% |
PHARMACEUTICAL | Oncology | ZYTIGA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 958 | 669 | $ 2,712 | 1,750
Percent Change (as a percent) | 43.20% |  | 55.00% |
PHARMACEUTICAL | Oncology | ZYTIGA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 527 | 352 | $ 1,420 | 826
Percent Change (as a percent) | 49.70% |  | 71.90% |
PHARMACEUTICAL | Oncology | ZYTIGA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 431 | 317 | $ 1,292 | 924
Percent Change (as a percent) | 36.00% |  | 39.80% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 156 | 127 | $ 426 | 384
Percent Change (as a percent) | 22.80% |  | 10.90% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 71 | 34 | $ 157 | 116
Percent Change (as a percent) |  |  | 35.30% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 85 | 93 | $ 269 | 268
Percent Change (as a percent) | (8.60%) |  | 0.40% |
PHARMACEUTICAL | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 656 | 632 | $ 1,906 | 717
Percent Change (as a percent) | 3.80% |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 425 | 371 | 1,215 | 408
Percent Change (as a percent) | 14.60% |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 231 | 261 | 691 | 309
Percent Change (as a percent) | (11.50%) |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 310 | 259 | 892 | 304
Percent Change (as a percent) | 19.70% |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 182 | 150 | 511 | 174
Percent Change (as a percent) | 21.30% |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 128 | 109 | 381 | 130
Percent Change (as a percent) | 17.40% |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 139 | 210 | 422 | 236
Percent Change (as a percent) | (33.80%) |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 69 | 83 | 208 | 85
Percent Change (as a percent) | (16.90%) |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 70 | 127 | 214 | 151
Percent Change (as a percent) | (44.90%) |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 171 | 124 | 482 | 133
Percent Change (as a percent) | 37.90% |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 154 | 113 | 433 | 121
Percent Change (as a percent) | 36.30% |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 17 | 11 | 49 | 12
Percent Change (as a percent) | 54.50% |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 36 | 39 | 110 | 44
Percent Change (as a percent) | (7.70%) |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 20 | 25 | 63 | 28
Percent Change (as a percent) | (20.00%) |  |  |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 16 | 14 | 47 | 16
Percent Change (as a percent) | 14.30% |  |  |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,391 | 1,585 | $ 4,426 | 4,665
Percent Change (as a percent) | (12.20%) |  | (5.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,026 | 1,179 | $ 3,230 | 3,488
Percent Change (as a percent) | (13.00%) |  | (7.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 365 | 406 | $ 1,196 | 1,177
Percent Change (as a percent) | (10.10%) |  | 1.60% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 334 | 447 | $ 1,137 | 1,291
Percent Change (as a percent) | (25.30%) |  | (11.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 86 | 156 | $ 315 | 464
Percent Change (as a percent) | (44.90%) |  | (32.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 248 | 291 | $ 822 | 827
Percent Change (as a percent) | (14.80%) |  | (0.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 612 | 635 | $ 1,869 | 1,790
Percent Change (as a percent) | (3.60%) |  | 4.40% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 612 | 635 | $ 1,869 | 1,790
Percent Change (as a percent) | (3.60%) |  | 4.40% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 190 | 265 | $ 653 | 844
Percent Change (as a percent) | (28.30%) |  | (22.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 150 | 220 | $ 523 | 723
Percent Change (as a percent) | (31.80%) |  | (27.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 40 | 45 | $ 130 | 121
Percent Change (as a percent) | (11.10%) |  | 7.40% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 255 | 238 | $ 767 | 740
Percent Change (as a percent) | 7.10% |  | 3.60% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 178 | 168 | $ 523 | 511
Percent Change (as a percent) | 6.00% |  | 2.30% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 77 | 70 | $ 244 | 229
Percent Change (as a percent) | 10.00% |  | 6.60% |
MEDICAL DEVICES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,587 | 6,599 | $ 20,326 | 19,618
Percent Change (as a percent) | (0.20%) |  | 3.60% |
MEDICAL DEVICES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,197 | 3,189 | $ 9,623 | 9,510
Percent Change (as a percent) | 0.30% |  | 1.20% |
MEDICAL DEVICES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,390 | 3,410 | $ 10,703 | 10,108
Percent Change (as a percent) | (0.60%) |  | 5.90% |
MEDICAL DEVICES | Diabetes Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 315 | 405 | $ 1,009 | 1,225
Percent Change (as a percent) | (22.20%) |  | (17.60%) |
MEDICAL DEVICES | Diabetes Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 125 | 168 | $ 371 | 482
Percent Change (as a percent) | (25.60%) |  | (23.00%) |
MEDICAL DEVICES | Diabetes Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 190 | 237 | $ 638 | 743
Percent Change (as a percent) | (19.80%) |  | (14.10%) |
MEDICAL DEVICES | Diagnostics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 1
MEDICAL DEVICES | Diagnostics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 0 | 0 | 0 | 0
MEDICAL DEVICES | Diagnostics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 0 | 0 | 0 | 1
MEDICAL DEVICES | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 653 | 553 | $ 1,960 | 1,675
Percent Change (as a percent) | 18.10% |  | 17.00% |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 320 | 279 | $ 947 | 843
Percent Change (as a percent) | 14.70% |  | 12.30% |
MEDICAL DEVICES | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 333 | 274 | $ 1,013 | 832
Percent Change (as a percent) | 21.50% |  | 21.80% |
MEDICAL DEVICES | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,111 | 2,204 | $ 6,623 | 6,772
Percent Change (as a percent) | (4.20%) |  | (2.20%) |
MEDICAL DEVICES | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,284 | 1,308 | $ 3,923 | 4,034
Percent Change (as a percent) | (1.80%) |  | (2.80%) |
MEDICAL DEVICES | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 827 | 896 | $ 2,700 | 2,738
Percent Change (as a percent) | (7.70%) |  | (1.40%) |
MEDICAL DEVICES | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 330 | 328 | $ 1,053 | 1,030
Percent Change (as a percent) | 0.60% |  | 2.20% |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 201 | 195 | $ 621 | 612
Percent Change (as a percent) | 3.10% |  | 1.50% |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 129 | 133 | $ 432 | 418
Percent Change (as a percent) | (3.00%) |  | 3.30% |
MEDICAL DEVICES | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 341 | 343 | $ 1,110 | 1,126
Percent Change (as a percent) | (0.60%) |  | (1.40%) |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 215 | 220 | $ 672 | 702
Percent Change (as a percent) | (2.30%) |  | (4.30%) |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 126 | 123 | $ 438 | 424
Percent Change (as a percent) | 2.40% |  | 3.30% |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 654 | 662 | $ 2,025 | 1,947
Percent Change (as a percent) | (1.20%) |  | 4.00% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 395 | 398 | $ 1,196 | 1,179
Percent Change (as a percent) | (0.80%) |  | 1.40% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 259 | 264 | $ 829 | 768
Percent Change (as a percent) | (1.90%) |  | 7.90% |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 786 | 871 | $ 2,435 | 2,669
Percent Change (as a percent) | (9.80%) |  | (8.80%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 473 | 495 | $ 1,434 | 1,541
Percent Change (as a percent) | (4.40%) |  | (6.90%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 313 | 376 | $ 1,001 | 1,128
Percent Change (as a percent) | (16.80%) |  | (11.30%) |
MEDICAL DEVICES | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,376 | 2,346 | $ 7,314 | 7,001
Percent Change (as a percent) | 1.30% |  | 4.50% |
MEDICAL DEVICES | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,016 | 1,002 | $ 3,031 | 3,009
Percent Change (as a percent) | 1.40% |  | 0.70% |
MEDICAL DEVICES | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,360 | 1,344 | $ 4,283 | 3,992
Percent Change (as a percent) | 1.20% |  | 7.30% |
MEDICAL DEVICES | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 976 | 923 | $ 2,947 | 2,733
Percent Change (as a percent) | 5.70% |  | 7.80% |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 421 | 398 | $ 1,216 | 1,190
Percent Change (as a percent) | 5.80% |  | 2.20% |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 555 | 525 | $ 1,731 | 1,543
Percent Change (as a percent) | 5.70% |  | 12.20% |
MEDICAL DEVICES | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,080 | 1,105 | $ 3,376 | 3,293
Percent Change (as a percent) | (2.30%) |  | 2.50% |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 423 | 430 | $ 1,282 | 1,276
Percent Change (as a percent) | (1.60%) |  | 0.50% |
MEDICAL DEVICES | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 657 | 675 | $ 2,094 | 2,017
Percent Change (as a percent) | (2.70%) |  | 3.80% |
MEDICAL DEVICES | Surgery | SPECIALTY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 320 | 318 | $ 991 | 975
Percent Change (as a percent) | 0.60% |  | 1.60% |
MEDICAL DEVICES | Surgery | SPECIALTY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 172 | 174 | $ 533 | 543
Percent Change (as a percent) | (1.10%) |  | (1.80%) |
MEDICAL DEVICES | Surgery | SPECIALTY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 148 | 144 | $ 458 | 432
Percent Change (as a percent) | 2.80% |  | 6.00% |
MEDICAL DEVICES | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,132 | 1,091 | $ 3,420 | 2,944
Percent Change (as a percent) | 3.80% |  | 16.20% |
MEDICAL DEVICES | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 452 | 432 | $ 1,351 | 1,142
Percent Change (as a percent) | 4.60% |  | 18.30% |
MEDICAL DEVICES | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 680 | 659 | $ 2,069 | 1,802
Percent Change (as a percent) | 3.20% |  | 14.80% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 835 | 800 | $ 2,486 | 2,236
Percent Change (as a percent) | 4.40% |  | 11.20% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 319 | 302 | $ 948 | 832
Percent Change (as a percent) | 5.60% |  | 13.90% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 516 | 498 | $ 1,538 | 1,404
Percent Change (as a percent) | 3.60% |  | 9.50% |
MEDICAL DEVICES | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 297 | 291 | $ 934 | 708
Percent Change (as a percent) | 2.10% |  | 31.90% |
MEDICAL DEVICES | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 133 | 130 | $ 403 | 310
Percent Change (as a percent) | 2.30% |  | 30.00% |
MEDICAL DEVICES | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 164 | $ 161 | $ 531 | $ 398
Percent Change (as a percent) | 1.90% |  | 33.40% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 32 -Paragraph 2A -URI http://asc.fasb.org/extlink&oid=82859839&loc=SL82860478-203043 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130539-203045 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_VELCADEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_TRACLEERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SPECIALTYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |